Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Nancy Kohl"'
Autor:
Manfred Kraus, Jannik N. Andersen, Peter Blume-Jensen, Nancy Kohl, Victoria Richon, Giulio Draetta, Martin L. Scott, Roderick T. Bronson, Shailaja Kasibhatla, Ekaterina V. Bobkova, Alan Northrup, Thomas F. Vogt, Myung K. Shin, Melissa Hurd, Paula Andrade, Erica Leccese, Minilik Angagaw, Nirah H. Shomer, Diana Gargano, Alessandra Di Bacco, Yusuf Erkul, Erin O'Hare, Kumiko Nagashima, Kun Hu, Yamicia Connor, Brian Dolinski, Kaiko Kunii, Heike Keilhack, Katharine Ellwood-Yen
Supplementary Figures 1-4 from PDK1 Attenuation Fails to Prevent Tumor Formation in PTEN-Deficient Transgenic Mouse Models
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::828919a62a5a02040e157eb5ac219fb4
https://doi.org/10.1158/0008-5472.22390089
https://doi.org/10.1158/0008-5472.22390089
Autor:
Karuppiah Kannan, Nancy Kohl, Murray O. Robinson, M. Isabel Chiu, Steve Clark, Tim Demuth, John F. Reilly, Christopher Winter, Chris Ware, Joerg Heyer, Jie Lin, Wenping Sun, Lingxin Kong, Carol Meeske, Sireesha Yalavarthi, Ruojie Wang, Pradip K. Majumder, Chun Cheng, James W. Watters
Notch pathway signaling plays a fundamental role in normal biological processes and is frequently deregulated in many cancers. Although several hypotheses regarding cancer subpopulations most likely to respond to therapies targeting the Notch pathway
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bde16d7f424b454e060ac021a814bec6
https://doi.org/10.1158/0008-5472.c.6500225.v1
https://doi.org/10.1158/0008-5472.c.6500225.v1
Autor:
James P. Stice, Sofia Donovan, Yuting Sun, Nancy Kohl, Barbara Czako, Faika Mseeh, Paul Leonard, Anna Wade, Justin Lim, Phil Jones, Eli Wallace, Kerstin Sinkevicius, Pedro Beltran
Publikováno v:
Molecular Cancer Therapeutics. 20:P207-P207
Src homology 2 domain-containing phosphatase (SHP2), a ubiquitously expressed non-receptor tyrosine phosphatase, plays a critical role in the regulation of the MAPK signaling pathway and cellular proliferation. Activating mutations in SHP2 are associ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fbd518f2371517aaa471c8cc35beac02
https://doi.org/10.1158/1535-7163.targ-21-p207
https://doi.org/10.1158/1535-7163.targ-21-p207
Autor:
Joseph L. Kim, Oleg Schmidt-Kittler, Yemarshet K. Gebreyohannes, Timothy Guzi, Kevin J. Wilson, Alison J. Davis, Alexandra K. Gardino, Adam Shutes, Christoph Lengauer, Lucian DiPietro, Stephen D. Miller, Brian L. Hodous, Yulian Zhang, Doug Wilson, Timothy LaBranche, Nicholas Lydon, Michael Heinrich, Nancy Kohl, Patrick Schöffski, Natasja Brooijmans, Agnieszka Wozniak, Erica Evans, Xing Julia Zhu, Daniel J. DeAngelo, Andy Boral, Beni B. Wolf
Publikováno v:
Science Translational Medicine. 9
Targeting oncogenic kinase drivers with small-molecule inhibitors can have marked therapeutic benefit, especially when administered to an appropriate genomically defined patient population. Cancer genomics and mechanistic studies have revealed that h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb6e3ad5639cb0b7a03fc75164a59dec
https://doi.org/10.1126/scitranslmed.aao1690
https://doi.org/10.1126/scitranslmed.aao1690
Autor:
Erica K, Evans, Alexandra K, Gardino, Joseph L, Kim, Brian L, Hodous, Adam, Shutes, Alison, Davis, Xing Julia, Zhu, Oleg, Schmidt-Kittler, Doug, Wilson, Kevin, Wilson, Lucian, DiPietro, Yulian, Zhang, Natasja, Brooijmans, Timothy P, LaBranche, Agnieszka, Wozniak, Yemarshet K, Gebreyohannes, Patrick, Schöffski, Michael C, Heinrich, Daniel J, DeAngelo, Stephen, Miller, Beni, Wolf, Nancy, Kohl, Timothy, Guzi, Nicholas, Lydon, Andy, Boral, Christoph, Lengauer
Publikováno v:
Science translational medicine. 9(414)
Targeting oncogenic kinase drivers with small-molecule inhibitors can have marked therapeutic benefit, especially when administered to an appropriate genomically defined patient population. Cancer genomics and mechanistic studies have revealed that h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::44c23e872b4ee8effe4e9b9a2cdce3de
https://pubmed.ncbi.nlm.nih.gov/30023395
https://pubmed.ncbi.nlm.nih.gov/30023395
Autor:
Sarah Klein, Praful Gokhale, Kristen Jones, Amy Saur, Scott Rodig, Xiaoyun Liao, Nancy Kohl, David Reardon, Gordon Freeman
Publikováno v:
The Journal of Immunology. 194:213.10-213.10
Glioblastoma presents a formidable obstacle for developing immunotherapeutic strategies due to a highly immunosuppressive systemic and micro-environment. Antibody blockade of co-inhibitory receptors CTLA-4 and PD-1 has been shown to overcome immunosu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b5e58ab781ad47ee504655567f8f9214
https://doi.org/10.4049/jimmunol.194.supp.213.10
https://doi.org/10.4049/jimmunol.194.supp.213.10